Table 3 Oncological detail of primary adrenal lymphoma.
Variables | Total cohort (n = 297) | Overall survival | F/χ2 | P | |
|---|---|---|---|---|---|
Dead (n = 198) | Alive (n = 99) | ||||
Side | |||||
 Unilateral | 201 (67.7) | 123 (61.2) | 78 (38.8) | 8.381 | 0.004* |
 Bilateral | 96 (32.3) | 75 (78.1) | 21 (21.9) | ||
SEER stage | |||||
 Localized | 103 (34.7) | 65 (63.1) | 38 (36.9) | 9.662 | 0.022* |
 Regional | 58 (19.5) | 33 (56.9) | 25 (43.1) | ||
 Distant | 95 (32.0) | 65 (68.4) | 30 (31.6) | ||
 Unstaged | 41 (13.8) | 35 (85.4) | 6 (14.6) | ||
AAC stage | |||||
 Stage I | 89 (30.0) | 66 (74.2) | 23 (25.8) | 30.495 |  < 0.001* |
Stage II | 54 (18.2) | 34 (63.0) | 20 (37.0) | ||
 Stage III | 13 (4.4) | 10 (76.9) | 3 (23.1) | ||
 Stage IV | 70 (23.6) | 58 (82.9) | 12 (17.1) | ||
 Unstaged | 71 (23.9) | 30 (42.3) | 41 (57.7) | ||
Pathology | |||||
 HL | 8 (2.7) | 4 (50.0) | 4 (50.0) | 24.371 | 0.041* |
 NSCHL | 4 (1.3) | 3 (75.0) | 1 (25.0) | ||
 MCCHL | 1 (0.3) | 0 (0.0) | 1 (100.0) | ||
 NOS | 3 (1.0) | 1 (33.3) | 2 (66.7) | ||
 NHL | 280 (94.3) | 185 (66.1) | 95 (33.9) | ||
 BCL | 254 (85.5) | 166 (65.4) | 88 (34.6) | ||
 DLBCL | 223 (75.1) | 146 (65.5) | 77 (34.5) | ||
 FL | 11 (3.7) | 5 (45.5) | 6 (54.5) | ||
 PCN | 6 (2.0) | 6 (100.0) | 0 (0.0) | ||
 BL | 4 (1.3) | 2 (50.0) | 2 (50.0) | ||
 CLL/SLL | 4 (1.3) | 4 (100.0) | 0 (0.0) | ||
 MALT | 4 (1.3) | 1 (25.0) | 3 (75.0) | ||
 MCL | 2 (0.7) | 2 (100.0) | 0 (0.0) | ||
 NKTCL | 8 (2.7) | 8 (100.0) | 0 (0.0) | ||
 PTCL | 6 (2.0) | 6 (100.0) | 0 (0.0) | ||
 ALCL | 1 (0.3) | 1 (100.0) | 0 (0.0) | ||
 ENKTCL | 1 (0.3) | 1 (100.0) | 0 (0.0) | ||
 NOS | 18 (6.1) | 11 (61.1) | 7 (38.9) | ||
 NOS | 9 (3.0) | 9 (100.0) | 0 (0.0) | ||
